Kamada Ltd (KMDA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Kamada Ltd (KMDA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH82415D
  • |
  • Pages: 58
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Kamada Ltd (Kamada) is a biopharmaceutical company that develops, manufactures and markets specialty proteins, specific immunoglobulins and other prescription medicines. The company's product include glassia, a intravenous plasma-derived alpha-1 antitrypsin product, which is used for the treatment of patients with emphysema secondary to congenital AAT deficiency. It also offers products for the treatment of cystic fibrosis, asthma, rabies, hepatitis B, and other indications. Kamada's pipeline products include intravenous and inhaled AAT protein and rabies. Its intravenous formulations are intended for GVHD, type-1 diabetes and lung transplantation indications. The company distributes its products through a network of distributors across Brazil, Israel, Russia, India and other countries in Eastern Europe, Latin America and Asia regions. Kamada is headquartered in Ness Ziona, Israel.

Kamada Ltd (KMDA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Kamada Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Kamada Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Kamada Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Kamada Enters into Partnership with Massachusetts General Hospital 11

Kamada Enters into Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 12

Kamada Partners with myTomorrows 13

Kamada Extends Distribution Agreement with Baxter International for Glassia 14

Kamada Extends Distribution Agreement With Baxter International For Glassia 16

Kamada Enters Into Distribution Agreement With Chiesi Farmaceutici For Alpha-1 Antitrypsin 18

Kamada Enters into Co-Marketing Agreement with Kedrion 19

Equity Offering 20

Kamada Raises USD15 Million in Public Offering of Shares 20

Kamada Completes Public Offering Of Shares For USD59 Million 22

Kamada Ltd-Key Competitors 23

Kamada Ltd-Key Employees 24

Kamada Ltd-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Financial Announcements 26

Aug 01, 2017: Kamada Reports Financial Results for Second Quarter and First Six Months of 2017 26

Jul 27, 2017: Kamada Pre-Announces Certain Preliminary Financial Results for Second Quarter and First Six Months of 2017 29

May 16, 2017: Kamada Reports 2017 First Quarter Financial Results 30

Feb 06, 2017: Kamada Reports Financial Results for the Fourth Quarter and Full-Year 2016 32

Nov 10, 2016: Kamada Reports Financial Results for the Third Quarter and Nine Months of 2016 35

Aug 02, 2016: Kamada Reports Financial Results for the Second Quarter and First Six Months of 2016 37

May 09, 2016: Kamada Reports 2016 First Quarter Financial Results 39

Feb 02, 2016: Kamada Reports 2015 Fourth Quarter and Full Year Financial Results 41

Corporate Communications 43

Feb 08, 2017: Kamada Announces Appointment of Biopharmaceutical Industry Veteran, Gwen Melincoff, to its Board of Directors 43

Government and Public Interest 44

Jun 27, 2016: BIRD-Israel-U.S. Binational Industrial R&D Foundation to Invest $7.5 Million in 9 New Projects 44

Product News 45

11/02/2016: Kamada Announces Plan for Phase 2/3 Clinical Trial with Alpha-1 Antitrypsin IV for Treatment of Graft-Versus-Host Disease 45

05/25/2016: Kamadas Alpha-1 Antitrypsin Now Available to Treat Graft-Versus-Host Disease on myTomorrows Early Access Platform 46

02/21/2017: Kamada Announces Collaboration with Massachusetts General Hospital for Proof of Concept Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation 47

01/23/2017: Kamada Announces Positive Scientific Advice Response from the European Medicines Agency Focused on Alpha-1 Antitrypsin IV for Treatment of Acute Graft-Versus-Host Disease 48

Product Approvals 49

Nov 07, 2016: Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin as a Post-Exposure Treatment 49

Sep 01, 2016: Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment 50

Jun 15, 2016: Shire and Kamada announce FDA approval of expanded label for self-infusion of Glassia for the treatment of emphysema due to severe AAT deficiency 51

Mar 28, 2016: Kamada Submits Marketing Authorization Application with the European Medicines Agency for its Proprietary Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency 52

Clinical Trials 54

May 24, 2017: Kamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference 54

Aug 30, 2016: Kamada Meets Primary Endpoint of U.S. Phase 2 Study of Inhaled Alpha-1 Antitrypsin for the Treatment of Alpha-1 Antitrypsin Deficiency 55

Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection 56

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58

List of Figures

Kamada Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Kamada Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Kamada Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Kamada Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Kamada Ltd, Deals By Therapy Area, 2011 to YTD 2017 9

Kamada Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Kamada Enters into Partnership with Massachusetts General Hospital 11

Kamada Enters into Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 12

Kamada Partners with myTomorrows 13

Kamada Extends Distribution Agreement with Baxter International for Glassia 14

Kamada Extends Distribution Agreement With Baxter International For Glassia 16

Kamada Enters Into Distribution Agreement With Chiesi Farmaceutici For Alpha-1 Antitrypsin 18

Kamada Enters into Co-Marketing Agreement with Kedrion 19

Kamada Raises USD15 Million in Public Offering of Shares 20

Kamada Completes Public Offering Of Shares For USD59 Million 22

Kamada Ltd, Key Competitors 23

Kamada Ltd, Key Employees 24

Kamada Ltd, Other Locations 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Kamada Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16020
Site License
USD 500 INR 32040
Corporate User License
USD 750 INR 48060

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com